Editas Medicine (EDIT) and Genevant Sciences said Monday they will combine Editas' CRISPR Cas12a genome editing systems with Genevant's LNP technology in the development of in vivo gene editing medicines for two targets in Editas' upregulation strategy.
Genevant granted Editas a nonexclusive license to exploit mRNA-CRISPR Cas12a-LNP products for the targets, with Genevant eligible to receive up to $238 million in upfront and contingent milestone payments, according to the companies.
Price: 3.8100, Change: +0.05, Percent Change: +1.33
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。